CaliPharms, Inc.
KGET
$0.00
$0.000.00%
OTC PK
| 09/30/2014 | 06/30/2014 | 03/31/2014 | |||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | -- | -- | -- | ||
| Cost of Revenue | -- | -- | -- | ||
| Gross Profit | -- | -- | -- | ||
| SG&A Expenses | 21.46% | 208.57% | 149.17% | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 57.99% | 305.33% | 168.03% | ||
| Operating Income | -25.53% | -242.67% | -153.18% | ||
| Income Before Tax | -2,161.95% | -2,375.47% | -493.94% | ||
| Income Tax Expenses | -- | -- | -- | ||
| Earnings from Continuing Operations | -2,161.95% | -2,375.47% | -493.94% | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -2,161.95% | -2,375.47% | -493.94% | ||
| EBIT | -25.53% | -242.67% | -153.18% | ||
| EBITDA | -- | -- | -- | ||
| EPS Basic | -- | -- | -- | ||
| Normalized Basic EPS | -- | -- | -- | ||
| EPS Diluted | -- | -- | -- | ||
| Normalized Diluted EPS | -- | -- | -- | ||
| Average Basic Shares Outstanding | -- | -- | -- | ||
| Average Diluted Shares Outstanding | -- | -- | -- | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||